Compare OLB & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLB | XRTX |
|---|---|---|
| Founded | 1993 | 2011 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4M | 4.3M |
| IPO Year | 2019 | 2018 |
| Metric | OLB | XRTX |
|---|---|---|
| Price | $0.31 | $2.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 260.8K | 10.5K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.48 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,676,907.00 | N/A |
| Revenue This Year | $12.19 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.24 | $0.35 |
| 52 Week High | $1.80 | $3.60 |
| Indicator | OLB | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.31 | 45.47 |
| Support Level | $0.27 | $2.00 |
| Resistance Level | $0.34 | $2.24 |
| Average True Range (ATR) | 0.03 | 0.11 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 56.20 | 12.12 |
The OLB Group Inc is a diversified FinTech company that focuses on a suite of products in the merchant services marketplace and seeks to provide integrated business solutions to merchants throughout the United States. The company seeks to provide merchants with a wide range-of-products and services through the various online platforms, including financial and transaction processing services. It also has products that provide support for crowdfunding and other capital-raising initiatives. It supplements the online platforms with certain hardware solutions that are integrated with the online platforms. The company has two business segments: Fintech Services, which generates key revenue, and the Bitcoin Mining business segment.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.